Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_assertion type Assertion NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_head.
- NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_provenance.
- NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_assertion evidence source_evidence_literature NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_provenance.
- NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_assertion SIO_000772 14755889 NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_provenance.
- NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_assertion wasDerivedFrom befree-2016 NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_provenance.
- NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_assertion wasGeneratedBy ECO_0000203 NP430302.RA1FCbdI-n7VqRYaj8thNhwGj4xkahku-5uPpiVaaTJwo130_provenance.